Zobrazeno 1 - 10
of 259
pro vyhledávání: '"James M, Boyett"'
Autor:
Tom Curran, Richard J. Gilbertson, James M. Boyett, Naoko Takebe, Dana Wallace, Murali Chintagumpala, Stewart Goldman, Roger J. Packer, Larry E. Kun, Sue Kaste, David W. Ellison, Clinton F. Stewart, Amar Gajjar
Purpose: To investigate the safety, dose-limiting toxicities, and pharmacokinetics of the smoothened inhibitor vismodegib in children with refractory or relapsed medulloblastoma.Experimental design: Initially, vismodegib was administered daily at 85
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::044aeb59b1dd16c65d049e326fb982ea
https://doi.org/10.1158/1078-0432.c.6522327
https://doi.org/10.1158/1078-0432.c.6522327
Autor:
Tom Curran, Richard J. Gilbertson, James M. Boyett, Naoko Takebe, Dana Wallace, Murali Chintagumpala, Stewart Goldman, Roger J. Packer, Larry E. Kun, Sue Kaste, David W. Ellison, Clinton F. Stewart, Amar Gajjar
PDF file - 156K, Supplementary Fig. S1. Concentration-time plots of the first 72 hours after administration of the first vismodegib dose during Course 1 to the patients in the initial cohort: 6 received 85 mg/m2 (Figure A & B), and 7 received 170 mg/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26899133026bacfbf4bfddf5759a4122
https://doi.org/10.1158/1078-0432.22451901
https://doi.org/10.1158/1078-0432.22451901
Autor:
Tom Curran, Richard J. Gilbertson, James M. Boyett, Naoko Takebe, Dana Wallace, Murali Chintagumpala, Stewart Goldman, Roger J. Packer, Larry E. Kun, Sue Kaste, David W. Ellison, Clinton F. Stewart, Amar Gajjar
PDF file - 104K, Supplementary Table S1. Vismodegib Dosing Strategy Supplementary Table S2. Commonly Reported Adverse Events According to Grade Supplementary Table S3. Pharmacokinetics of Unbound Vismodegib in Pediatric Patients with Medulloblastoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1065899e0687d584c3cca4ce9b81772f
https://doi.org/10.1158/1078-0432.22451898.v1
https://doi.org/10.1158/1078-0432.22451898.v1
Autor:
Sarah Leary, Girish Dhall, Shannon M. MacDonald, Aashim Bhatia, James M. Boyett, Maryam Fouladi, Shengjie Wu, Amar Gajjar, Jason Fangusaro, Mark M. Souweidane, Soumen Khatua, Sunita K. Patel, Erin S Murphy, Ute Bartels, Leanne Embry, Christine L. Trask, Dennis Shaw, Arzu Onar-Thomas
Publikováno v:
Neuro Oncol
Background The study aimed to evaluate whether simplified chemotherapy followed by dose-reduced irradiation was effective for treating patients (ages 3–21 years) with localized germinoma. The primary endpoint was 3-year progression-free survival (P
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6af0e4003d9b5b20d143e336fc32953
https://europepmc.org/articles/PMC9159444/
https://europepmc.org/articles/PMC9159444/
Autor:
Ibrahim eQaddoumi, Mehmet eKocak, Atmaram S. Pai-Panandiker, Gregory T. Armstrong, Cynthia eWetmore, John R. Crawford, Tong eLin, James M Boyett, Larry E. Kun, Fredrick A. Boop, Thomas E. Merchant, David W Ellison, Amar eGajjar, Alberto eBroniscer
Publikováno v:
Frontiers in Oncology, Vol 4 (2014)
Background. Epidermal growth factor receptor is overexpressed in most pediatric high-grade gliomas (HGG). Since erlotinib had shown activity in adults with HGG, we conducted a phase II trial of erlotinib and local radiotherapy in children with newly
Externí odkaz:
https://doaj.org/article/102abc8e336441c8bd6189bc470514b0
Autor:
Bernadine eDonahue, n/a en/a, MaryAnne H. Marymont, Sandra eKessel, Matthew K. Iandoli, Thomas eFitzGerald, Emiko eHolmes, Mehmet eKocak, James M. Boyett, Amar eGajjar, Roger J. Packer
Publikováno v:
Frontiers in Oncology, Vol 2 (2012)
Purpose: Associations of RT deviations and outcomes in medulloblastoma have not been defined well, particularly in the era of reduced-dose CSI and chemotherapy. The aim of this study is to evaluate the quality of RT on CCG/POG 9961 and analyze associ
Externí odkaz:
https://doaj.org/article/2b8e7c474273453c9ffbd45b74f0a53e
Autor:
Gerald A. Grant, Peter C. Phillips, Renée M Reynolds, Elizabeth A. Reap, Mehmet Kocak, Arzu Onar-Thomas, Sridharan Gururangan, Duane Mitchell, Robert J. Schmittling, James M. Boyett, Patricia Baxter, Ian F. Pollack, Maryam Fouladi
Publikováno v:
Cancer Immunology, Immunotherapy. 66:1589-1595
We evaluated circulating levels of immunosuppressive regulatory T cells (Tregs) and other lymphocyte subsets in patients with newly diagnosed medulloblastoma (MBL) undergoing surgery compared to a control cohort of patients undergo craniectomy for co
Autor:
Stewart Goldman, Kathleen Dorris, Maryam Fouladi, Roger J. Packer, Paul G. Fisher, Vinay M. Daryani, Shaoyu Li, Shiva Senthil Kumar, Tong Lin, James M. Boyett, Tina Young Poussaint, Clinton F. Stewart, Ralph Salloum, Lili Miles, Ian F. Pollack, Charles B. Stevenson, Rachid Drissi, Girish Dhall, Trent R. Hummel
Publikováno v:
Journal of Neuro-Oncology. 129:443-451
Telomerase activation is critical in many cancers including central nervous system (CNS) tumors. Imetelstat is an oligonucleotide that binds to the template region of the RNA component of telomerase, inhibiting its enzymatic activity. We conducted an
Autor:
Rachel Tanos, Sarah Leary, Susan M. Blaney, Kelly C. Goldsmith, Vinay M. Daryani, Clinton F. Stewart, Amar Gajjar, Cynthia Wetmore, James M. Boyett, Catherine A. Billups
Publikováno v:
Cancer Medicine
Sunitinib malate is a small multi‐targeted tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor (PDGFR) and stem cell factor receptor (KIT), which are highly expresse
Autor:
Jonathan L. Finlay, Peter C. Burger, Ian F. Pollack, Floyd H. Gilles, Allen J. Yates, Jeffrey C. Allen, Richard L. Davis, Laurence E. Becker, Eric Bouffet, James M. Boyett
Publikováno v:
Journal of Neurosurgery: Pediatrics. 17:453-459
OBJECT The impact of central pathology review on outcome has been described in pediatric patients with high-grade glioma (HGG). The objective of this report was to analyze the impact of the central pathology review on outcome in the subgroup of patie